---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-150518"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:20:03.655747+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Carl Morris resigns as CSO Neuromuscular; Jennifer Marlowe to become CSO

## Summary
- Carl Morris resigns as Chief Scientific Officer, Neuromuscular, effective July 14, 2023.
- Jennifer Marlowe, current CSO Friedreich's Ataxia and Cardiac Pipeline, will assume role of CSO.
- Morris receives severance: 1 year base salary, COBRA for 12 months, $172,200 lump sum (100% of 2023 target bonus).
- Morris to enter consulting agreement through March 31, 2024; time-based equity awards continue vesting.

## SEC filing metadata
- accession: 0001193125-23-150518
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312523150518/0001193125-23-150518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312523150518/d696236d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-150518
- JSON: https://secwatch.observer/filing/0001193125-23-150518.json
- Plain text: https://secwatch.observer/filing/0001193125-23-150518.txt

## Key facts
- Executive change
  Jennifer Marlowe was appointed as Chief Scientific Officer at Solid Biosciences Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: Following the Separation Date, Jennifer Marlowe, Chief Scientific Officer, Friedreich’s Ataxia and Cardiac Pipeline of the Company, will assume Dr. Morris’ responsibilities and serve as Chief Scientific Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312523150518/0001193125-23-150518-index.htm
- Executive change
  Carl Morris resigned as Chief Scientific Officer, Neuromuscular at Solid Biosciences Inc..
  - Action: resigned
  - Role: Chief Scientific Officer, Neuromuscular
  source text: On May 22, 2023, Solid Biosciences Inc. (the “Company”) and Carl Morris entered into an executive transition and separation agreement (the “Separation Agreement”) providing for Dr. Morris’ resignation as Chief Scientific Officer, Neuromuscular of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312523150518/0001193125-23-150518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.